Research progress on drug resistance mechanism of sorafenib in radioiodine refractory differentiated thyroid cancer
10.13699/j.cnki.1001-6821.2024.13.029
- VernacularTitle:索拉非尼在碘难治性分化型甲状腺癌中耐药机制现状
- Author:
En-Tao ZHANG
1
;
Hao-Nan ZHU
;
Zheng-Ze WEN
;
Cen-Hui ZHANG
;
Yi-Huan ZHAO
;
Ying-Jie MAO
;
Jun-Pu WU
;
Yu-Cheng JIN
;
Xin JIN
Author Information
1. 绍兴文理学院医学院,浙江绍兴 312000
- Keywords:
radioactive iodine-refractory differentiated thyroid cancer;
sorafenib;
drug resistance mechanism;
synergistic effect;
mitogen-activated protein kinase pathway;
phosphatidylinositol-3-kinase pathway
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(13):1986-1990
- CountryChina
- Language:Chinese
-
Abstract:
Most patients with differentiated thyroid cancer have a good prognosis after radioiodine-131 therapy,but a small number of patients are insensitive to radioiodine-131 therapy and even continue to develop disease.At present,some targeted drugs can improve progression-free survival in patients with radioactive iodine-refractory differentiated thyroid cancer(RAIR-DTC),such as sorafenib and levatinib,have been approved for the treatment of RAIR-DTC.However,due to the presence of primary and acquired drug resistance,drug efficacy in these patients is unsatisfactory.This review introduces the acquired drug resistance mechanism of sorafenib in the regulation of mitogen-activated protein kinase(MAPK)and phosphatidylinositol-3-kinase(PI3K)pathways and proposes related treatment strategies,in order to provide a reference for similar drug resistance mechanism of sorafenib and effective treatment of RAIR-DTC.
